1.11 Capital expenditure

In 2020, the tangible capital expenditure resulting from UCB biopharmaceutical activities amounted to € 256 million (2019: €  99 million) and are mainly related to the new campus site in the UK and the Bioplant in Belgium.

1.12 Statement of financial position

The intangible assets increased by € 2 134 million from € 839 million at December 31, 2019 to € 2 973 million at December 31, 2020.